ReviewJournal of otology2017
Intratympanic corticosteroids in Ménière's disease: A mini-review.
Review in Journal of otology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Intratympanic corticosteroids for Ménière's disease.The Cochrane database of systematic reviews · 2023Pooled it
- Effects of intratympanic gentamicin and intratympanic glucocorticoids in Ménière's disease: a network meta-analysis.Journal of neurology · 2022Pooled it
- Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic.European annals of otorhinolaryngology, head and neck diseases · 2020Guideline
- Epidemiological and clinical differences in Meniere disease across European and East Asian populations.The Journal of international medical research · 2026Review
- Ménière's Disease: Treatment Options, Dietary Restrictions, and Lifestyle Modifications.Journal of pharmacy & bioallied sciences · 2026Review
- Immunological mechanisms in Meniere's disease.Frontiers in immunology · 2025Review
- Precision medicine: a new era for inner ear diseases.Frontiers in pharmacology · 2024Review
- Development and In-Silico and Ex-Vivo Validation of a Software for a Semi-Automated Segmentation of the Round Window Niche to Design a Patient Specific Implant to Treat Inner Ear Disorders.Journal of imaging · 2023Article
- Article
- Prolonged Dexamethasone Exposure Enhances Zebrafish Lateral-Line Regeneration But Disrupts Mitochondrial Homeostasis and Hair Cell Function.Journal of the Association for Research in Otolaryngology : JARO · 2022Article
- Repurposable Drugs That Interact with Steroid Responsive Gene Targets for Inner Ear Disease.Biomolecules · 2022Article
- Quality of life after intratympanic steroid injection for Ménière's disease.Laryngoscope investigative otolaryngology · 2022Article
- A Perspective for Ménière's Disease: In Silico Investigations of Dexamethasone as a Direct Modulator of AQP2.Biomolecules · 2022Article
- Hearing Function, Degeneration, and Disease: Spotlight on the Stria Vascularis.Frontiers in cell and developmental biology · 2022Review
- Current Insights into Treating Vertigo in Older Adults.Drugs & aging · 2021Review
- Determination of the Round Window Niche Anatomy Using Cone Beam Computed Tomography Imaging as Preparatory Work for Individualized Drug-Releasing Implants.Journal of imaging · 2021Article
- Use of Super Paramagnetic Iron Oxide Nanoparticles as Drug Carriers in Brain and Ear: State of the Art and Challenges.Brain sciences · 2021Review
- Causes and treatment of idiopathic benign paroxysmal positional vertigo based on endocrinological and other metabolic factors.Journal of otology · 2020Review
- Pharmacological, Surgical and Diagnostic Innovations in Meniere's Disease: A Review.Translational medicine @ UniSa · 2020Article
- Steroid Nomenclature in Inner Ear Therapy.Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article reviews the effectiveness of intratympanic corticosteroids for vertigo control in Ménière's disease at 2-years follow-up according to the guidelines expressed by the American Academy of Otolaryngology-Head & Neck Surgery. Despite the increased use of intratympanic corticosteroids for vertigo control in Ménière's disease there is debate as to their effectiveness, particularly compared to gentamicin. Even so, after just a single course of injections, corticosteroids can reliably provide complete vertigo control (Class A) at 2-years in about 50% of cases as indicated in a recent double-blind randomized controlled clinical trial (Patel et al., 2016). But the effectiveness of intratympanic corticosteroids truly increases when treatment is provided 'as-needed', whereby complete vertigo control is established in up to 91% of cases. On the basis of available literature, there is good evidence to recommend the use of intratympanic steroid treatment for vertigo control in Ménière's disease, but patients must be monitored for non-response. The rationale for treating patients as-needed and the possible reasons for corticosteroid non-response are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.